MANTLE CELL LYMPHOMA

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to seek out and destroy cancer cells while sparing healthy ones. The study aims to fin…

This study tests a new drug called BGB-16673 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The goal is to find the best dose and see if it is safe and shrinks tumors. About 146 Chinese adults will take part in this …

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of targeted drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test whether carefully managing any new or wors…

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study tests a combination of two drugs, zanubrutinib and tafasitamab, in adults with mantle cell lymphoma, a type of blood cancer. The goal is to find the best dose and see how well the treatment shrinks tumors. About 27 people will take part in this early-phase trial.

This early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…

This early-phase trial tests a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cell…

This study is testing whether a new type of radiation therapy guided by MRI is safe and works well for people with gastric, breast, or other cancers. About 70 adults will receive this treatment along with chemotherapy. The goal is to see if the MRI guidance helps doctors target t…

This study is testing a new drug called AZD0486, either by itself or with other cancer treatments, in people with certain types of blood cancers like chronic lymphocytic leukemia and lymphoma. The main goals are to check if the drug is safe and to find the best dose. About 408 pa…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma that has come back or not responded to treatment, as well as for those who haven't been treated yet. The goal is to find the best dose and see how many…

This study tests whether combining two drugs—glofitamab and pirtobrutinib—is safe and works better than current options for people with mantle cell lymphoma that has returned or not responded to prior treatment. About 30 adults will receive the combo and be monitored for side eff…

This early-phase study is testing a new treatment for adults with certain types of blood cancer (B-cell lymphomas) that have returned or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (LV20.19 CAR…

This study tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas. Participants must have tried at least two prior treatments without success or had side effects. The main goals ar…

This study tests whether a combination of three drugs—acalabrutinib, obinutuzumab, and glofitamab—is safe and effective for people with mantle cell lymphoma that has come back or not improved after prior treatment. About 40 adults will receive these medications to see if the canc…

This study tests a new combination of drugs (bendamustine, rituximab, cytarabine, and zanubrutinib) as initial treatment for mantle cell lymphoma, followed by a maintenance phase with or without an additional drug (sonrotoclax). The goal is to see if this approach leads to a comp…

This study tests whether combining two drugs, pirtobrutinib and venetoclax, can help control mantle cell lymphoma (MCL) that has returned or not responded to prior therapy. About 30 adults with confirmed MCL will take both pills by mouth. The goal is to see how many patients' tum…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…

This study tests a three-drug combination (obinutuzumab, zanubrutinib, and lenalidomide) as a first treatment for people with mantle cell lymphoma who have never had therapy. About 37 adults aged 18-80 will receive the drugs, and those at higher risk may also get CAR-T cell thera…

This study tests a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated, slow-growing types of non-Hodgkin lymphoma, including follicular lymphoma. The goal is to see if this drug pair can shrink or eliminate cancer. About 49 adults will take part. T…

This study tests a drug called acalabrutinib combined with standard chemotherapy (R-CHOP) in 55 adults with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see how well the combination shrinks tumors and controls the disease. Participants wil…

This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for si…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests whether adding a third drug (cytarabine) to the standard two-drug chemo regimen can help older adults with mantle cell lymphoma live longer without their cancer growing. The trial enrolls 90 patients aged 70+ (or 60+ if not eligible for transplant) who have not y…

This study tests whether combining three drugs (glofitamab, venetoclax, and lenalidomide) can safely treat people newly diagnosed with a high-risk form of mantle cell lymphoma. About 50 adults aged 18 to 80 will receive the combination to see if it improves cancer control. The go…

This study is testing whether adding an experimental drug called venetoclax to two standard drugs (lenalidomide and rituximab) is safe and works well for people with untreated mantle cell lymphoma, a rare blood cancer. About 28 adults will take the three drugs together. The goal …

This study tests a combination of two drugs—glofitamab and ibrutinib—plus a pretreatment drug called obinutuzumab for people with mantle cell lymphoma who are 65 or older, or younger adults with high-risk features. The goal is to see if this combo is safe and can shrink or elimin…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…

This study offers a CAR T-cell therapy called brexucabtagene autoleucel to people with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially made treatment batch didn't pass quality checks. Participants must have a batch that still meets the study's safety stand…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…

This study tests whether a faster dose increase of the drug sonrotoclax, given with other medicines, is safe for people with certain blood cancers (CLL, SLL, or mantle cell lymphoma). The cancers may be new, returned, or not responding to treatment. The goal is to see if this qui…

This study tests a drug called pemigatinib in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The main goal is to see if the drug can shrink tumors. About 27 people will take part, and the study is cu…

This study tests a chemotherapy-free combination of two drugs—pirtobrutinib (a pill) and rituximab (an infusion)—in 50 adults newly diagnosed with low- or intermediate-risk mantle cell lymphoma. The goal is to see if this approach can provide long-term remission while avoiding tr…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This phase 3 study tests a new drug called rocbrutinib against other targeted therapies (BTK inhibitors) for people with mantle cell lymphoma that has come back or stopped responding to treatment. About 394 adults who have had at least one prior therapy will be randomly assigned …

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This study tests whether adding the drug pirtobrutinib to standard CAR-T cell therapy (brexu-cel) can improve outcomes for adults with mantle cell lymphoma that has come back or not responded to treatment. About 60 participants will be randomly assigned to receive pirtobrutinib e…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests a new treatment called CTX112 for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor immune cells that can target and kill cancer cells. The trial…

This early-phase study is testing whether it is safe and possible to collect a patient's own stem cells and give them together with CAR T-cell therapy for blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain types of lymphoma…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main go…

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This study looks at whether older patients with mantle cell lymphoma can safely stop taking zanubrutinib after their cancer goes into remission, and only restart it if the cancer returns. Currently, patients take this drug every day indefinitely, which can be costly and cause sid…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This study tests whether a new targeted drug (nemtabrutinib) combined with an immune-boosting antibody (rituximab) can shrink or eliminate mantle cell lymphoma in people who haven't had treatment yet. About 27 adults will receive the drug combination, and doctors will measure how…

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…

This study tests a new type of PET scan that targets a protein called CD70, which is found on some cancer cells. The goal is to see if this scan can better detect kidney cancer, lymphoma, and nasopharyngeal cancer compared to standard scans. About 300 adults with known or suspect…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home care and if it is safe. Participants will receive their usual cancer drugs either at home or in the clini…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study watches how certain blood cancer drugs (BTK inhibitors or venetoclax) affect the heart's rhythm. About 135 adults with cancers like CLL or mantle cell lymphoma will have heart tests before and during treatment. The goal is to spot dangerous heart rhythms early and unde…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at how the flu and COVID vaccines affect the immune system in people with different types of lymphoma. Researchers will measure antibody levels and immune cells over time, comparing them to people without lymphoma. The goal is to better understand how lymphoma an…

This study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…